GNA Biosolutions

GNA Biosolutions is a startup founded in 2017 based in Germany. Its most recent tracked round is Series C+. Brouky classifies it under Healthcare & Life Sciences. Brouky records 5 investors associated with the company.

GNA Biosolutions develops molecular diagnostic technologies, including the GNA Neo rapid diagnostic system that can test up to eight samples simultaneously near the point of care. Its platform has been used with more than 30 assays for research and diagnostics, including MRSA, tuberculosis, Ebola and plague.